Moreover, patients with a CD4+ T cell count < 200/μL had a dismal median OS of 7 weeks, compared to those cases with a CD4+ T cell count > 200/μL who experienced a median OS of 7 months, suggesting that immune function may show a favorable impact on AML prognosis [39]. This evidence concerns the gene CD4 and acute myeloid leukemia.